Ardelyx Inc (ARDX)
8.465
-0.82
(-8.78%)
USD |
NASDAQ |
May 08, 16:00
8.45
-0.02
(-0.18%)
After-Hours: 20:00
Ardelyx Cash from Investing (Quarterly): -2.572M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.572M |
| December 31, 2023 | -29.57M |
| September 30, 2023 | -32.70M |
| June 30, 2023 | -59.21M |
| March 31, 2023 | -9.777M |
| December 31, 2022 | 1.441M |
| September 30, 2022 | -0.832M |
| June 30, 2022 | 15.47M |
| March 31, 2022 | 2.332M |
| December 31, 2021 | 22.10M |
| September 30, 2021 | 18.13M |
| June 30, 2021 | 8.234M |
| March 31, 2021 | 2.485M |
| December 31, 2020 | -3.57M |
| September 30, 2020 | 9.594M |
| June 30, 2020 | 13.42M |
| March 31, 2020 | -50.88M |
| December 31, 2019 | -55.46M |
| September 30, 2019 | 23.45M |
| June 30, 2019 | 25.40M |
| March 31, 2019 | 29.98M |
| December 31, 2018 | 22.19M |
| September 30, 2018 | 10.09M |
| Date | Value |
|---|---|
| June 30, 2018 | -61.04M |
| March 31, 2018 | -1.135M |
| December 31, 2017 | 11.22M |
| September 30, 2017 | 14.81M |
| June 30, 2017 | 16.29M |
| March 31, 2017 | 22.97M |
| December 31, 2016 | -59.23M |
| September 30, 2016 | -71.35M |
| June 30, 2016 | -0.295M |
| March 31, 2016 | -0.20M |
| December 31, 2015 | -0.454M |
| September 30, 2015 | -0.68M |
| June 30, 2015 | -1.265M |
| March 31, 2015 | -1.055M |
| December 31, 2014 | -1.032M |
| September 30, 2014 | -0.088M |
| June 30, 2014 | -0.642M |
| March 31, 2014 | -0.094M |
| December 31, 2013 | 0.00 |
| September 30, 2013 | -0.021M |
| June 30, 2013 | -0.187M |
| March 31, 2013 | -0.07M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-59.21M
Minimum
Jun 2023
25.40M
Maximum
Jun 2019
-5.125M
Average
1.886M
Median
Cash from Investing (Quarterly) Benchmarks
| Nektar Therapeutics | 17.38M |
| Rigel Pharmaceuticals Inc | -6.874M |
| Omeros Corp | 116.24M |
| Vistagen Therapeutics Inc | -0.0323M |
| Karyopharm Therapeutics Inc | 26.84M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -35.72M |
| Cash from Financing (Quarterly) | 52.97M |
| Free Cash Flow | -81.12M |
| Free Cash Flow Per Share (Quarterly) | -0.1539 |
| Free Cash Flow to Equity (Quarterly) | -85.88M |
| Free Cash Flow to Firm (Quarterly) | -31.80M |
| Free Cash Flow Yield | -4.22% |